AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, issued the following letter to its shareholders and the investment community from its newly appointed CEO, James Sapirstein.
October 22, 2019
· 6 min read